Other substances

Dolutegravir

A HIV integrase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Dolutegravir is a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor. Orally bioavailable, it prevents HIV genome integration into host DNA (NCIt).

Dolutegravir on DrugBank
Dolutegravir on PubChem
Dolutegravir on Wikipedia

Marketed as

TIVICAY (DOLUTEGRAVIR SODIUM); TIVICAY PD (DOLUTEGRAVIR SODIUM)

C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server	in silico	4.55	Predicted to bind a SARS-CoV-2 protein structural feature.	Aug/11/2020
Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay Preprint Screening	in vitro		inhibitor of the ACE2-RBD interaction	Jun/16/2020
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach 3CLpro RdRpol Small molecule In silico	in silico	2.45	Predicted to bind both SARS-CoV-2 3C-like protease and RNA-dependent RNA polymerase. It also possesses predicted good bioavailability.	Oct/26/2020
Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein Spike protein Small molecule In silico	in silico	2.74	Predicted to bind SARS-CoV-2 Spike protein. The drug's "BD-2" derivative was predicted to have an enhanced capability to disrupt RBD binding to ACE2.	Jan/25/2021

AI-suggested references

Link	Publication date
In silico screening of phytochemical compounds and FDA drugs as potential inhibitors for NSP16/10 5' methyl transferase activity.	Sep/23/2021
Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.	Apr/06/2022
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients	Jul/28/2021
Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase	Apr/20/2020
Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs	Apr/11/2020
RHAMNETIN IS A BETTER INHIBITOR OF SARS-COV-2 2'-O-METHYLTRANSFERASE THAN DOLUTEGRAVIR: A COMPUTATIONAL PREDICTION	Nov/24/2021
Tocilizumab in HIV patient with severe COVID-19: case report	Oct/16/2021
In-silico drug repurposing for targeting SARS-CoV-2 main protease (Mpro)	Feb/06/2022
Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach	Sep/22/2021
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	Feb/16/2021

Export (.csv)